Abbott Laboratories (NYSE:ABT) delivered better-than-expected first-quarter earnings and held firm on its full-year guidance, even as parts of its business felt the impact of a challenging macro environment.
The company reported adjusted earnings of $1.09 per share for the quarter, surpassing analyst expectations of $1.07 and improving from $0.98 a year earlier. Total revenue rose 4% year-over-year to $10.36 billion, just shy of the $10.4 billion forecast.
One of the quarter’s key growth drivers was Abbott’s diabetes care segment, which saw a 16% surge in revenue to $1.83 billion, fueled by continued demand for its FreeStyle Libre glucose monitoring system. That strength helped push total medical device sales to $4.9 billion.
However, softness in the diagnostics division weighed on results, with revenue from that unit falling 7.2% to $2.05 billion—below analysts’ estimates of $2.19 billion.
Despite mixed segment performance, Abbott reiterated its full-year 2025 guidance. The company still expects organic sales growth between 7.5% and 8.5%, and adjusted EPS in the range of $5.05 to $5.25. For the current quarter, adjusted earnings are projected between $1.23 and $1.27 per share.